bg content top home

Smarter science.
Better health.

SEPTEMBER 2016

RDD Pharma, a leader in developing treatments for anorectal disroders, announces that it has been granted patents in the EU, China, and Russia for developing methods for treating fecal incontinence. The patents are based in part on the increase in resting pressure via a topical administration of RDD 0315, an alpha-agonist.

  • RDD 0315 is currently being studied in the treatment of fecal incontinence associated with spinal cord injury (SCI). A successful placebo-controlled Phase 2a study was recently completed showing statistical significance and a ~25% reduction in unwanted fecal incontinence episodes in SCI patients. Good tolerability and safety was also observed, with no systemic absorption as indicated by plasma levels of RDD-0315 being below detectable limits.
  • RDD Pharma is also currently enrolling patients in a multicenter European Phase 3 study in chronic anal fissure.
Target-icon

Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.

VISIT OUR TARGET PAGE

Strategey-icon

Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.

VISIT OUR STRATEGY PAGE

Pipeline-icon

Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).

VISIT OUR PIPELINE PAGE

video

Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.

WATCH OUR VIDEO

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2016, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top